08:00 , Nov 2, 2009 |  BC Week In Review  |  Company News

Telormedix management update

Telormedix S.A. , Bioggio, Switzerland   Business: Cancer   Hired: Johanna Holldack as CEO, formerly CEO of Borean Pharma A/S  ...
01:12 , Oct 28, 2009 |  BC Extra  |  Company News

Telormedix names Holldack CEO

Cancer company Telormedix S.A. (Bioggio, Switzerland) hired Johanna Holldack as CEO. Holldack is the former CEO of Borean Pharma A/S . Telormedix was founded in 2007 ( See BioCentury, Oct. 20, 2008 )....
08:00 , Jan 12, 2009 |  BioCentury  |  Emerging Company Profile

Anaphore: Narrowing the focus

Anaphore Inc. was founded in late 2007 to commercialize a protein engineering platform that had been the basis of now defunct Borean Pharma A/S . Anaphore believes focusing on specific products against a few carefully...
07:00 , Sep 17, 2007 |  BC Week In Review  |  Company News

Borean, Eden Biodesign deal

Eden will manufacture preclinical batches of Borean's MBP- DC-SIGN to treat cancer. The product is a mannose-binding protein (MBP)-derived compound that causes complement-induced lysis. Further details were not disclosed. Borean Pharma A/S , Aarhus, Denmark...
07:00 , May 15, 2006 |  BC Week In Review  |  Company News

Borean, Roche deal

Borean granted ROCZ exclusive rights to develop and commercialize Trimeric Apo A-I to treat atherosclerosis. The trimerized version of the naturally occurring apolipoprotein A-I (Apo A-I) is entering lead optimization. Further terms were not disclosed....
07:00 , May 15, 2006 |  BioCentury  |  Strategy

Next-generation protein players

Next-generation protein players Company Platform 4-Antibody Uses genetically modified preB cells, which can develop into human antibody producing cells, to generate optimized antibodies Ablynx Developing nanobodies, or single-domain antibodies, which combine advantages of antibody therapeutics...
00:21 , May 9, 2006 |  BC Extra  |  Company News

Roche in-licenses Borean's Trimeric Apo A-I

Borean (Aarhus, Denmark) granted Roche (SWX:ROCZ) exclusive rights to develop and commercialize Trimeric Apo A-I to treat atherosclerosis. The trimerized version of the naturally occurring apolipoprotein A-I (Apo A-I) is entering lead optimization. Further terms...
08:00 , Dec 12, 2005 |  BC Week In Review  |  Clinical News

Borean preclinical data

In a transgenic mouse model of RA a TNF alpha antagonist significantly reduced disease progression and was equivalent to Remicade compared to control. The tumor necrosis factor (TNF) alpha antagonist was derived from Borean's C-type...
07:00 , Aug 22, 2005 |  BioCentury  |  Emerging Company Profile

Cerenis: Synthesize, don't mimic

Drugs such as statins can reduce circulating cholesterol and prevent the progression of atherosclerotic plaques, but none are able to promote the regression of plaques. Cerenis Therapeutics Holding SA says that it can address this...
07:00 , May 30, 2005 |  BC Week In Review  |  Company News

Borean management update

Borean Pharma A/S , Aarhus, Denmark   Business: Cardiovascular, Combinatorial biology   Hired: John Nieland as VP of preclinical research, formerly director of research at MediGene AG  ...